HALO vs. MNTA, CBPO, TWST, IOVA, NVAX, BMRN, INCY, UTHR, NBIX, and EXAS
Should you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Momenta Pharmaceuticals (MNTA), China Biologic Products (CBPO), Twist Bioscience (TWST), Iovance Biotherapeutics (IOVA), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), and Exact Sciences (EXAS). These companies are all part of the "medical" sector.
Momenta Pharmaceuticals (NASDAQ:MNTA) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends.
Halozyme Therapeutics has higher revenue and earnings than Momenta Pharmaceuticals. Momenta Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Halozyme Therapeutics has a consensus price target of $58.38, suggesting a potential upside of 3.81%. Given Momenta Pharmaceuticals' higher probable upside, analysts clearly believe Halozyme Therapeutics is more favorable than Momenta Pharmaceuticals.
97.8% of Halozyme Therapeutics shares are held by institutional investors. 3.4% of Momenta Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Momenta Pharmaceuticals has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
Momenta Pharmaceuticals received 60 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. However, 69.21% of users gave Halozyme Therapeutics an outperform vote while only 66.59% of users gave Momenta Pharmaceuticals an outperform vote.
Halozyme Therapeutics has a net margin of 36.94% compared to Halozyme Therapeutics' net margin of -757.61%. Momenta Pharmaceuticals' return on equity of 225.71% beat Halozyme Therapeutics' return on equity.
In the previous week, Halozyme Therapeutics had 18 more articles in the media than Momenta Pharmaceuticals. MarketBeat recorded 18 mentions for Halozyme Therapeutics and 0 mentions for Momenta Pharmaceuticals. Momenta Pharmaceuticals' average media sentiment score of 0.76 beat Halozyme Therapeutics' score of 0.00 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.
Summary
Halozyme Therapeutics beats Momenta Pharmaceuticals on 13 of the 17 factors compared between the two stocks.
Get Halozyme Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Halozyme Therapeutics Competitors List
Related Companies and Tools
Free HALO Stock Alerts